Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics cash
Cash and short-term investments held at the end of each period.
Insight Molecular Diagnostics's cash was $17.76M at Jun 30, 2026. For fiscal 2025 it was $11.58M, up 34.1% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $32.95M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.58M | +34.1% |
| FY2024 | Dec 31, 2024 | $8.64M | -8.4% |
| FY2023 | Dec 31, 2023 | $9.43M | -52.8% |
| FY2022 | Dec 31, 2022 | $19.99M | -39.3% |
| FY2021 | Dec 31, 2021 | $32.95M | +361.3% |
| FY2020 | Dec 31, 2020 | $7.14M | -67.6% |
| FY2019 | Dec 31, 2019 | $22.07M | +174.7% |
| FY2018 | Dec 31, 2018 | $8.03M | +5.7% |
| FY2017 | Dec 31, 2017 | $7.60M | -25.3% |
| FY2016 | Dec 31, 2016 | $10.17M | +27.2% |
| FY2015 | Dec 31, 2015 | $8.00M | +3011.3% |
| FY2014 | Dec 31, 2014 | $257.00K | +154.5% |
| FY2013 | Dec 31, 2013 | $101.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.76M | -26.9% |
| Q1 FY2026 | Mar 31, 2026 | $28.20M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $11.58M | +34.1% |
| Q3 FY2025 | Sep 30, 2025 | $18.69M | +455.8% |
| Q2 FY2025 | Jun 30, 2025 | $24.29M | +162.4% |
| Q1 FY2025 | Mar 31, 2025 | $31.03M | +456.3% |
| Q4 FY2024 | Dec 31, 2024 | $8.64M | -8.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.36M | -75.6% |
| Q2 FY2024 | Jun 30, 2024 | $9.26M | -46.7% |
| Q1 FY2024 | Mar 31, 2024 | $5.58M | -52.7% |
| Q4 FY2023 | Dec 31, 2023 | $9.43M | -52.8% |
| Q3 FY2023 | Sep 30, 2023 | $13.78M | -57.0% |
| Q2 FY2023 | Jun 30, 2023 | $17.37M | -61.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.80M | -42.2% |
| Q4 FY2022 | Dec 31, 2022 | $19.99M | -39.3% |
| Q3 FY2022 | Sep 30, 2022 | $32.05M | -26.0% |
| Q2 FY2022 | Jun 30, 2022 | $44.84M | -3.5% |
| Q1 FY2022 | Mar 31, 2022 | $20.41M | -65.3% |
| Q4 FY2021 | Dec 31, 2021 | $32.95M | +361.3% |
| Q3 FY2021 | Sep 30, 2021 | $43.34M | +321.1% |
| Q2 FY2021 | Jun 30, 2021 | $46.47M | +176.7% |
| Q1 FY2021 | Mar 31, 2021 | $58.91M | +255.4% |
| Q4 FY2020 | Dec 31, 2020 | $7.14M | -67.6% |
| Q3 FY2020 | Sep 30, 2020 | $10.29M | -47.1% |
| Q2 FY2020 | Jun 30, 2020 | $16.80M | -53.1% |
| Q1 FY2020 | Mar 31, 2020 | $16.58M | -57.8% |
| Q4 FY2019 | Dec 31, 2019 | $22.07M | +174.7% |
| Q3 FY2019 | Sep 30, 2019 | $19.44M | +79.7% |
| Q2 FY2019 | Jun 30, 2019 | $35.83M | +248.0% |
| Q1 FY2019 | Mar 31, 2019 | $39.26M | +211.3% |
| Q4 FY2018 | Dec 31, 2018 | $8.03M | +5.7% |
| Q3 FY2018 | Sep 30, 2018 | $10.82M | -1.8% |
| Q2 FY2018 | Jun 30, 2018 | $10.29M | +19.1% |
| Q1 FY2018 | Mar 31, 2018 | $12.61M | +11.1% |
| Q4 FY2017 | Dec 31, 2017 | $7.60M | -25.3% |
| Q3 FY2017 | Sep 30, 2017 | $11.02M | -13.0% |
| Q2 FY2017 | Jun 30, 2017 | $8.64M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.17M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.67M | – |
See a number that looks wrong?